Update of the statements on biology and clinical impact of occult hepatitis B virus infection.
J Hepatol. 2019; 71: 397-408
Hepatitis B virus infection and transfusion medicine: science and the occult.
Transfusion. 2008; 48: 1001-1026
Occult hepatitis B.
Lancet Infect Dis. 2002; 2: 479-486
Asymptomatic Hepadnaviral Persistence and Its Consequences in the Woodchuck Model of Occult Hepatitis B Virus Infection.
J Clin Transl Hepatol. 2015; 3: 211-219
Occult lifelong persistence of infectious hepadnavirus and residual liver inflammation in woodchucks convalescent from acute viral hepatitis.
Hepatology. 1999; 29: 928-938
Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation.
Journal of hepatology. 2000; 33: 992-997
Hepatitis B virus pre-S/S variants in liver diseases.
World J Gastroenterol. 2018; 24: 1507-1520
Occult hepatitis B virus infection in anti-HBs-positive infants born to HBsAg-positive mothers in China.
PLoS One. 2013; 8e70768
Occult hepatitis B virus infection in hepatitis B vaccinated children in Taiwan.
J Hepatol. 2009; 50: 264-272
High prevalence of occult hepatitis B virus infection in children born to HBsAg-positive mothers despite prophylaxis with hepatitis B vaccination and HBIG.
J Hepatol. 2012; 57: 515-521
Hepatitis B vaccination with or without hepatitis B immunoglobulin at birth to babies born of HBsAg-positive mothers prevents overt HBV transmission but may not prevent occult HBV infection in babies: a randomized controlled trial.
J Viral Hepat. 2013; 20: 801-810
T cell responses and viral variability in blood donation candidates with occult hepatitis B infection.
J Hepatol. 2012; 56: 765-774
The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response.
Nat Med. 1996; 2: 1104-1108
Long-lasting memory T cell responses following self-limited acute hepatitis B.
J Clin Invest. 1996; 98: 1185-1194
Application of a newly developed high-sensitivity HBsAg chemiluminescent enzyme immunoassay for hepatitis B patients with HBsAg seroclearance.
J Clin Microbiol. 2013; 51: 3484-3491
Highly sensitive detection of hepatitis B virus surface antigen by use of a semiautomated immune complex transfer chemiluminescence enzyme immunoassay.
J Clin Microbiol. 2013; 51: 2238-2244
Among Patients with Undetectable Hepatitis B Surface Antigen and Hepatocellular Carcinoma, a High Proportion Has Integration of HBV DNA into Hepatocyte DNA and No Cirrhosis.
Clin Gastroenterol Hepatol. 2020; 18: 449-456
Occult hepatitis B virus infection.
Transfus Clin Biol. 2004; 11: 18-25
Correlation between anti-HBc titers and HBV DNA in blood units without detectable HBsAg.
Vox Sang. 1992; 63: 107-111
Occult Hepatitis B (OBH) in Clinical Settings.
Hepat Mon. 2012; 12e6126
Occult hepatitis B virus infection and hepatocellular carcinoma: a systematic review.
J Viral Hepat. 2014; 21: 153-162
Occult hepatitis B virus infection: a covert operation.
J Viral Hepat. 2010; 17: 1-15
Occult HBV Infection May Be Transmitted through Close Contact and Manifest as an Overt Infection.
PLoS One. 2015; 10e0138552
International forum on Occult hepatitis B infection and transfusion safety.
Vox Sang. 2019; 114: 397-406
Detection of different categories of hepatitis B virus (HBV) infection in a multi-regional study comparing the clinical sensitivity of hepatitis B surface antigen and HBV-DNA testing.
Transfusion. 2017; 57: 24-35
Occult hepatitis B infection in blood donors from South East Asia: molecular characterisation and potential mechanisms of occurrence.
Gut. 2012; 61: 1744-1753
Hepatitis B Core-Related Antigen: A Serum Biomarker for Intrahepatic Covalently-Closed-Circular DNA.
Clin Lab. 2018; 64: 411-412
Multiple HBV transfusion transmissions from undetected occult infections: revising the minimal infectious dose.
Gut. 2019; 68: 313-321
Infectivity of blood components from donors with occult hepatitis B infection – results from an Australian lookback programme.
Vox Sang. 2015; 108: 113-122
Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program.
Transfusion. 2007; 47: 1197-1205
Rare transmission of hepatitis B virus by Dutch donors with occult infection.
Transfusion. 2016; 56: 691-698
Residual risk of transfusion-transmitted hepatitis B virus (HBV) infection caused by blood components derived from donors with occult HBV infection in Japan.
Transfusion. 2013; 53: 1393-1404
Infectivity of blood products from donors with occult hepatitis B virus infection.
Transfusion. 2013; 53: 1405-1415
Ferguson M, Health A, Lelie N, ubling M, Nick S, Gerlich W, et al. WHO Working Group on Hepatitis and HIV Diagnostic Kits : report of a collaborative study to 1) assess the suitability of candidate replacement international standard for HBsAG and a reference panel for HBsAG and 2) to calibrate the candidate standard in IU. World Health Organization. 2003.
Quantification of hepatitis B virus genomes and infectivity in human serum samples.
Transfusion. 2006; 46: 1829-1835
Molecular analysis of the hepatitis B virus presurface and surface gene in patients from eastern China with occult hepatitis B.
J Med Virol. 2013; 85: 979-986
Impact of “a” determinant mutations on detection of hepatitis B surface antigen (HBsAg) in HBV strains from Chinese patients with occult hepatitis B.
J Med Virol. 2017; 89: 1796-1803
Occult HBV infection in Chinese blood donors: role of N-glycosylation mutations and amino acid substitutions in S protein transmembrane domains.
Emerg Microbes Infect. 2019; 8: 1337-1346
Antigenicity reduction contributes mostly to poor detectability of HBsAg by hepatitis B virus (HBV) S-gene mutants isolated from individuals with occult HBV infection.
J Med Virol. 2018; 90: 263-270
Comprehensive genetic and epigenetic analysis of occult hepatitis B from liver tissue samples.
Clin Infect Dis. 2008; 46: 1227-1236
Sequence variations of full-length hepatitis B virus genomes in Chinese patients with HBsAg-negative hepatitis B infection.
PLoS One. 2014; 9e99028
Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma.
Hepatology. 2007; 45: 277-285
Transmissibility of hepatitis B virus (HBV) infection through blood transfusion from blood donors with occult HBV infection.
Clin Infect Dis. 2011; 52: 624-632
Occult Hepatitis-B Virus as Source of Infection in Liver-Transplant Recipients.
Lancet. 1994; 343: 142-146
Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study.
J Clin Oncol. 2014; 32: 3736-3743
Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study.
Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions.
Gastroenterology. 2017; 152: 1297-1309
Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection.
Gastroenterology. 2004; 126: 102-110
Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma.
Hepatology. 2011; 54: 829-836
Evidence that methylation of hepatitis B virus covalently closed circular DNA in liver tissues of patients with chronic hepatitis B modulates HBV replication.
J Med Virol. 2009; 81: 1177-1183
Transcription of hepatitis B virus covalently closed circular DNA is regulated by CpG methylation during chronic infection.
PLoS One. 2014; 9e110442
Epigenetic regulation of hepatitis B virus covalently closed circular DNA: Implications for epigenetic therapy against chronic hepatitis B.
Hepatology. 2017; 66: 2066-2077
Structural organization of the hepatitis B virus minichromosome.
J Mol Biol. 2001; 307: 183-196
Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones.
Gastroenterology. 2006; 130: 823-837
Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function.
Proc Natl Acad Sci U S A. 2009; 106: 19975-19979
Role of hepatitis B core protein in HBV transcription and recruitment of histone acetyltransferases to cccDNA minichromosome.
Antiviral Research. 2017; 144: 1-7
HBV X protein mutations affect HBV transcription and association of histone-modifying enzymes with covalently closed circular DNA.
Sci Rep. 2020; 10: 802
IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome.
J Clin Invest. 2012; 122: 529-537
Methyltransferase PRMT1 is a binding partner of HBx and a negative regulator of hepatitis B virus transcription.
J Virol. 2013; 87: 4360-4371
PRMT5 restricts hepatitis B virus replication through epigenetic repression of covalently closed circular DNA transcription and interference with pregenomic RNA encapsidation.
Hepatology. 2017; 66: 398-415
Interplay between SIRT1 and hepatitis B virus X protein in the activation of viral transcription.
Biochim Biophys Acta Gene Regul Mech. 2017; 1860: 491-501
Control of cccDNA function in hepatitis B virus infection.
J Hepatol. 2009; 51: 581-592
The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection.
Gastroenterology. 2008; 134: 1470-1481
Hepatocellular carcinoma in woodchuck hepatitis virus-infected woodchucks: presence of viral DNA in tumor tissue from chronic carriers and animals serologically recovered from acute infections.
Hepatology. 1989; 9: 461-470
Low doses of hepadnavirus induce infection of the lymphatic system that does not engage the liver.
J Virol. 2004; 78: 1730-1738
Repeated exposure to trace amounts of woodchuck hepadnavirus induces molecularly evident infection and virus-specific T cell response in the absence of serological infection markers and hepatitis.
J Virol. 2013; 87: 1035-1048
FDA: Increased HBV reactivation risk with ofatumumab or rituximab.
JAMA. 2013; 310: 1664
Differential Expression of Woodchuck Toll-Like Receptors 1-10 in Distinct Forms of Infection and Stages of Hepatitis in Experimental Hepatitis B Virus Infection.
Front Microbiol. 2018; 9: 3007
Primary seronegative but molecularly evident hepadnaviral infection engages liver and induces hepatocarcinoma in the woodchuck model of hepatitis B.
PLoS Pathog. 2014; 10e1004332
HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma.
Gastroenterology. 2008; 135: 1192-1199
Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
J Hepatol. 2017; 67: 902-908
Prevalence of occult hepatitis B virus infection among hepatopathy patients and healthy people in China.
J Infect. 2009; 58: 383-388
Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study.
J Viral Hepat. 2009; 16: 437-443
Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis.
Liver Int. 2012; 32: 231-240
Virologic analysis of non-B, non-C hepatocellular carcinoma in Japan: frequent involvement of hepatitis B virus.
J Infect Dis. 2000; 181: 1920-1928
A study on sequence variations in pre-S/surface, X and enhancer II/core promoter/precore regions of occult hepatitis B virus in non-B, non-C hepatocellular carcinoma patients in Taiwan.
Int J Cancer. 2009; 125: 621-629
Virological significance of low-level hepatitis B virus infection in patients with hepatitis C virus associated liver disease.
J Med Virol. 2004; 72: 223-229
Occult hepatitis B virus infection in patients with chronic liver disease due to hepatitis C virus and hepatocellular carcinoma in Brazil.
Arq Gastroenterol. 2007; 44: 58-63
Hepatitis B virus DNA in liver tissue and risk for hepatocarcinogenesis in patients with hepatitis C virus-related chronic liver disease. A prospective study.
Intervirology. 2008; 51: 59-68
Survey of hepatitis B virus co-infection in hepatitis C virus-infected patients suffering from chronic hepatitis and hepatocellular carcinoma in Japan.
Jpn J Cancer Res. 1999; 90: 1270-1272
HBsAg-negative hepatitis B virus infections in hepatitis C virus-associated hepatocellular carcinoma.
J Viral Hepat. 2005; 12: 325-329
Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C.
Hepatology. 2011; 54: 434-442
Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C.
J Clin Microbiol. 2002; 40: 4068-4071
Clinicopathological study of occult hepatitis B virus infection in hepatitis C virus-associated hepatocellular carcinoma.
Eur J Gastroenterol Hepatol. 2019; 31: 716-722
Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients.
Cancer. 2006; 106: 1326-1330
Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C.
J Hepatol. 2013; 59: 696-700
Occult hepatitis B virus infection as a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C in whom viral eradication fails.
Hepatol Res. 2008; 38: 546-556
Influence of occult hepatitis B virus coinfection on the incidence of fibrosis and hepatocellular carcinoma in chronic hepatitis C.
Intervirology. 2008; 51: 352-361
Occult HBV infection.
Semin Immunopathol. 2013; 35: 39-52
Current Knowledge of Occult Hepatitis B Infection and Clinical Implications.
Semin Liver Dis. 2019; 39: 249-260
Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: Old and new paradigms.
Gastroenterology. 2004; 127: S56-S61
Viral integration drives multifocal HCC during the occult HBV infection.
J Exp Clin Cancer Res. 2019; 38: 261
Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer.
Nat Genet. 2016; 48: 500-509
Hepatitis B virus (HBV) DNA integration in patients with occult HBV infection and hepatocellular carcinoma.
Liver Int. 2015; 35: 2311-2317
Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas.
Gut. 2005; 54: 1162-1168
Sequencing of human-viral DNA junctions in hepatocellular carcinoma from patients with HCV and occult HBV infection.
J Med Virol. 2003; 69: 475-481
Mechanisms of HBV-induced hepatocellular carcinoma.
J Hepatol. 2016; 64: S84-S101
The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma.
J Hepatol. 2005; 42: 760-777
Identification of hepatitis B virus integration in hepatitis C virus-infected hepatocellular carcinoma tissues.
J Hepatol. 1997; 26: 771-778
Expression of mutated hepatitis B virus X genes in human hepatocellular carcinomas.
Int J Cancer. 1999; 80: 497-505
Hepatitis B virus-related insertional mutagenesis implicates SERCA1 gene in the control of apoptosis.
Oncogene. 2000; 19: 2877-2886
Hepatitis B virus DNA integration in tumour tissue of a non-cirrhotic HFE-haemochromatosis patient with hepatocellular carcinoma.
J Hepatol. 2013; 58: 190-193
HBV DNA integration and HBV-transcript expression in non-B, non-C hepatocellular carcinoma in Japan.
J Med Virol. 2003; 71: 492-498
Alterations of tumor suppressor genes and allelic losses in human hepatocellular carcinomas in China.
Cancer Res. 1994; 54: 281-285
Genetic heterogeneity of hepatocellular carcinoma.
Proc Natl Acad Sci U S A. 1994; 91: 822-826
HBV genome integration and genetic instability in HBsAg-negative and anti-HCV-positive hepatocellular carcinoma in Japan.
Cancer Lett. 1997; 119: 53-61
Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma.
Hepatology. 1995; 21: 313-321
Deletion mutants of the hepatitis B virus X gene in human hepatocellular carcinoma.
Biochem Biophys Res Commun. 1997; 241: 726-729
Characterisation of hepatitis B virus X protein mutants in tumour and non-tumour liver cells using laser capture microdissection.
J Hepatol. 2003; 39: 253-261
Cytosol is the prime compartment of hepatitis B virus X protein where it colocalizes with the proteasome.
Oncogene. 1998; 16: 2051-2063
Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues.
Cancer Res. 2001; 61: 7803-7810
Quasispecies variant of pre-S/S gene in HBV-related hepatocellular carcinoma with HBs antigen positive and occult infection.
Infect Agent Cancer. 2018; 13: 7
Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications.
J Hepatol. 2014; 61: 408-417
Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis.
Hepatology. 1998; 28: 231-236
Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection.
Gastroenterology. 2002; 123: 1084-1089
HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects.
Hepatology. 2004; 39: 1694-1701
Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance.
J Hepatol. 2005; 42: 188-194
Hepatitis B virus persistence after recovery from acute viral hepatitis.
J Clin Invest. 1994; 93: 230-239
Persistent viremia after recovery from self-limited acute hepatitis B.
Hepatology. 1998; 27: 1377-1382
Long-term histologic and virologic outcomes of acute self-limited hepatitis B.
Hepatology. 2003; 37: 1172-1179
Liver enzyme flares and occult hepatitis B in persons with chronic hepatitis C infection.
J Clin Virol. 2007; 39: 101-105
Close monitoring of serum HBV DNA levels and liver enzymes levels is most useful in the management of patients with occult HBV infection.
J Hepatol. 2009; 51: 824-825
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.
Hepatology. 2018; 67: 1560-1599